Thursday, November 12, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 17, 2026

JPMorgan Chase (JPM) Stock After 25% Yearly Gain Is The Price Still Reasonable

View original at finance.yahoo.com
JPMorgan Chase (JPM) Stock After 25% Yearly Gain Is The Price Still Reasonable Never miss an important update on your stock portfolio and cut through the noise…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The average Return on Equity used in the Excess Returns model is 16.96%, with a cost of equity of US$11.65 per share and an excess return of US$13.00 per share

    60% confidence

  • Over 7 million investors trust Simply Wall St for stock portfolio updates

    60% confidence

  • JPMorgan Chase scores just 2 out of 6 on Simply Wall St's valuation checks, with multiple red flags identified

    60% confidence

  • JPMorgan Chase stock is approximately 24.0% undervalued based on the Excess Returns valuation model, with an intrinsic value estimate of US$435.81 per share versus a market price of US$331.14

    60% confidence

  • Analysts estimate a stable earnings figure of US$24.65 per share and a stable book value of US$145.37 per share for JPMorgan Chase, based on forward-looking ROE inputs from 12 analysts

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com
JPMorgan Chase (JPM) Stock After 25% Yearly Gain Is The Price Still Reasonable — Source | Via News | Via News